Search

Your search keyword '"Matsubara N"' showing total 953 results

Search Constraints

Start Over You searched for: Author "Matsubara N" Remove constraint Author: "Matsubara N"
953 results on '"Matsubara N"'

Search Results

1. Does antimicrobial use density at the ward level influence monthly central line-associated bloodstream infection rates?

2. Association between ward-specific antimicrobial use density and methicillin-resistant Staphylococcus aureus surveillance: a 60-month study

3. The Duel of Magnetic Interactions & Structural Instabilities: Itinerant Frustration in the Triangular Lattice Compound LiCrSe$_2$

4. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe$_2$ investigated by $\mu^+$SR as well as neutron and X-ray diffraction

5. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

6. Neutron powder diffraction study of NaMn$_2$O$_4$ and Li$_{0.92}$Mn$_2$O$_4$: New insights on spin-charge-orbital ordering

7. Magnetism and Ion Diffusion in Honeycomb Layered Oxide K$_2$Ni$_2$TeO$_6$: First Time Study by Muon Spin Rotation & Neutron Scattering

9. Genomic profiling and clinical utility of circulating tumor DNA in metastatic renal cell carcinoma: Nationwide SCRUM-Japan MONSTAR SCREEN project

10. The TALAPRO-3 study design: a plain language summary.

11. Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.

13. Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

14. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

15. CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

16. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe2 investigated by $$\mu ^+$$SR, neutron and X-ray diffraction

17. 264P Increased membrane HER3 expression in brain metastases compared to primary tumors in breast cancer

18. 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011

19. 1423TiP CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

20. LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study

21. 1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C

22. 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study

23. 1626P Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations

25. 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

27. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

28. Surgeons' fear of getting infected by COVID19: A global survey

29. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic

30. Surgeons' fear of getting infected by COVID19: A global survey

31. A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

32. Nuclear and magnetic spin structure of the antiferromagnetic triangular lattice compound LiCrTe2 investigated by mu+SR, neutron and X-ray diffraction

33. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

34. Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

35. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie

36. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

37. 545P First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part

39. 617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project

40. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma

41. 585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)

42. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility

43. Study of γ d → π + π − d Reaction in an Energy Region of 0.67 ≤ E γ ≤ 1.08 GeV

44. P108 - Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) + novel hormonal therapy (NHT) combination therapy

50. 1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2

Catalog

Books, media, physical & digital resources